The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1544-1552

  Bellani, Marcella ^a   Dusi, Nicola ^a   Yeh, Ping Hong ^b   Soares, Jair C ^c   Brambilla, Paolo ^d,e  

^a UNIVERSITY OF VERONA   (Italy)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF UDINE   (Italy)

^e SCIENTIFIC INSTITUTE   (Italy)

Author keywords

MRI; MRS; PET; Serotonin; SPECT

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FENOZOLONE; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PLACEBO; REBOXETINE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; BRAIN REGION; BRAIN SIZE; COGNITION; COGNITIVE THERAPY; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MOTOR PERFORMANCE; NEUROANATOMY; NEUROCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; SENSORIMOTOR FUNCTION; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS; TREATMENT DURATION; WORKING MEMORY;

ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE;

EID: 79961127497     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.040     Document Type: Article

References (126)

1. Alavi A., Dann R., Chawluk J., Alavi J., Kushner M., Reivich M. Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med 1986, 16:2-34.
2. Anderson I.M., Del-Ben C.M., McKie S., Richardson P., Williams S.R., Elliott R., Deakin J.F. Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. NeuroReport 2007, 18:1351-1355.
3. Arce E., Simmons A.N., Lovero K.L., Stein M.B., Paulus M.P. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl) 2008, 196:661-672.
4. Bearden CE, Thompson PM, Avedissian C, Klunder AD, Nicoletti M, Dierschke N, Brambilla P, Soares JC. Altered hippocampal morphology in unmedicated patients with major depressive illness. ASN Neuro 2009; 1.
5. Bellani M., Cerruti S., Brambilla P. Orbitofrontal cortex abnormalities in schizophrenia. Epidemiol Psichiatr Soc 2010, 19:23-25.
6. Benedetti F., Radaelli D., Bernasconi A., Dallaspezia S., Colombo C., Smeraldi E. Changes in medial prefrontal cortex neural responses parallel successful antidepressant combination of venlafaxine and light therapy. Arch Ital Biol 2009, 147:83-93.
7. Bhagwagar Z., Wylezinska M., Taylor M., Jezzard P., Matthews P.M., Cowen P.J. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 2004, 161:368-370.
8. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Boorman E., Matthews M., Cowen J. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008, 11:255-260.
9. Bigos K.L., Pollock B.G., Aizenstein H.J., Fisher P.M., Bies R.R., Hariri A.R. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 2008, 33:3221-3225.
10. Brambilla P., Barale F., Caverzasi E., Soares J.C. Anatomical MRI findings in mood and anxiety disorders. Epidemiol Psichiatr Soc 2002, 11:88-99.
11. Brambilla P., Nicoletti M.A., Harenski K., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology 2002, 27:792-799.
12. Brambilla P., Stanley J.A., Nicoletti M., Harenski K., Wells K.F., Mallinger A.G., Keshavan M.S., Soares J.C. 1H MRS brain measures and acute lorazepam administration in healthy human subjects. Neuropsychopharmacology 2002, 26:546-551.
13. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003, 8:721-737. 715.
14. Brambilla P., Nicoletti M., Sassi R.B., Mallinger A.G., Frank E., Keshavan M.S., Soares J.C. Corpus callosum signal intensity in patients with bipolar and unipolar disorder. J Neurol Neurosurg Psychiatry 2004, 75:221-225.
15. Brambilla P., Stanley J.A., Sassi R.B., Nicoletti M.A., Mallinger A.G., Keshavan M.S., Soares J.C. 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 2004, 29:1918-1924.
16. Brambilla P., Cipriani A., Hotopf M., Barbui C. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry 2005, 38:69-77.
17. Brambilla P., Stanley J.A., Nicoletti M.A., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. 1H Magnetic resonance spectroscopy study of dorsolateral prefrontal cortex in unipolar mood disorder patients. Psychiatry Res 2005, 138:131-139.
18. Brockmann H., Zobel A., Joe A., Biermann K., Scheef L., Schuhmacher A., von W.O., Metten M., Biersack H.J., Maier W., Boecker H. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression. Psychiatry Res 2009, 173:107-112.
19. Brody A.L., Saxena S., Silverman D.H., Alborzian S., Fairbanks L.A., Phelps M.E., Huang S.C., Wu H.M., Maidment K., Baxter L.R. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res 1999, 91:127-139.
20. Brody A.L., Barsom M.W., Bota R.G., Saxena S. Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Semin Clin Neuropsychiatry 2001, 6:102-112.
21. Brody A.L., Saxena S., Stoessel P., Gillies L.A., Fairbanks L.A., Alborzian S., Phelps M.E., Huang S.C., Wu H.M., Ho M.L., Ho M.K., Au S.C., Maidment K., Baxter L.R. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001, 58:631-640.
22. Bruhl A.B., Kaffenberger T., Herwig U. Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology 2010, 35:521-533.
23. Buchsbaum M.S., Wu J., Siegel B.V., Hackett E., Trenary M., Abel L., Reynolds C. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997, 41:15-22.
24. Buchsbaum M.S., Wu J., Siegel B.V., Hackett E., Trenary M., Abel L., Reynolds C. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997, 41:15-22.
25. Buchsbaum M.S., Hollander E., Haznedar M.M., Tang C., Spiegel-Cohen J., Wei T.C., Solimando A., Buchsbaum B.R., Robins D., Bienstock C., Cartwright C., Mosovich S. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 2001, 4:119-125.
26. Buffalari D.M., Grace A.A. Noradrenergic modulation of basolateral amygdala neuronal activity: opposing influences of alpha-2 and beta receptor activation. J Neurosci 2007, 27:12358-12366.
27. Caetano S.C., Sassi R., Brambilla P., Harenski K., Nicoletti M., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. MRI study of thalamic volumes in bipolar and unipolar patients and healthy individuals. Psychiatry Res 2001, 108:161-168.
28. Caetano S.C., Hatch J.P., Brambilla P., Sassi R.B., Nicoletti M., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. Psychiatry Res 2004, 132:141-147.
29. Caetano S.C., Kaur S., Brambilla P., Nicoletti M., Hatch J.P., Sassi R.B., Mallinger A.G., Keshavan M.S., Kupfer D.J., Frank E., Soares J.C. Smaller cingulate volumes in unipolar depressed patients. Biol Psychiatry 2006, 59:702-706.
30. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004, 161:598-607.
31. Cipriani A., Brambilla P., Furukawa T., Geddes J., Gregis M., Hotopf M., Malvini L., Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005, CD004185.
32. Clark D.M., Teasdale J.D. Diurnal variation in clinical depression and accessibility of memories of positive and negative experiences. J Abnorm Psychol 1982, 91:87-95.
33. Costafreda S.G., Brammer M.J., David A.S., Fu C.H. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain Res Rev 2008, 58:57-70.
34. Coull J.T. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 1998, 55:343-361.
35. Davidson R.J., Irwin W. The functional neuroanatomy of emotion and affective style. Trends Cogn Sci 1999, 3:11-21.
36. Davidson R.J., Irwin W., Anderle M.J., Kalin N.H. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003, 160:64-75.
37. Davies J., Lloyd K.R., Jones I.K., Barnes A., Pilowsky L.S. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. Am J Psychiatry 2003, 160:374-376.
38. Deakin J.F. The role of serotonin in panic, anxiety and depression. Int Clin Psychopharmacol 1998, 13(4):S1-S5.
39. Del-Ben C.M., Deakin J.F., McKie S., Delvai N.A., Williams S.R., Elliott R., Dolan M., Anderson I.M. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 2005, 30:1724-1734.
40. Drevets W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000, 126:413-431.
41. Drevets W.C. Neuroimaging studies of mood disorders. Biol Psychiatry 2000, 48:813-829.
42. Elliott R., Rubinsztein J.S., Sahakian B.J., Dolan R.J. The neural basis of mood-congruent processing biases in depression. Arch Gen Psychiatry 2002, 59:597-604.
43. Fitzgerald D.A., Angstadt M., Jelsone L.M., Nathan P.J., Phan K.L. Beyond threat: amygdala reactivity across multiple expressions of facial affect. Neuroimage 2006, 30:1441-1448.
44. Frey R., Metzler D., Fischer P., Heiden A., Scharfetter J., Moser E., Kasper S. Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5tesla. J Psychiatr Res 1998, 32:411-420.
45. Frodl T., Jager M., Smajstrlova I., Born C., Bottlender R., Palladino T., Reiser M., Moller H.J., Meisenzahl E.M. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci 2008, 33:423-430.
46. Fu C.H., Williams S.C., Cleare A.J., Brammer M.J., Walsh N.D., Kim J., Andrew C.M., Pich E.M., Williams P.M., Reed L.J., Mitterschiffthaler M.T., Suckling J., Bullmore E.T. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004, 61:877-889.
47. Fu C.H., Williams S.C., Brammer M.J., Suckling J., Kim J., Cleare A.J., Walsh N.D., Mitterschiffthaler M.T., Andrew C.M., Pich E.M., Bullmore E.T. Neural responses to happy facial expressions in major depression following antidepressant treatment. Am J Psychiatry 2007, 164:599-607.
48. Hamilton J.P., Siemer M., Gotlib I.H. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Mol Psychiatry 2008, 13:993-1000.
49. Harmer C.J., Mackay C.E., Reid C.B., Cowen P.J., Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006, 59:816-820.
50. Hasler G., Neumeister A., van D.V., Tumonis T., Bain E.E., Shen J., Drevets W.C., Charney D.S. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 2005, 58:969-973.
51. Hyder F., Patel A.B., Gjedde A., Rothman D.L., Behar K.L., Shulman R.G. Neuronal-glial glucose oxidation and glutamatergic-GABAergic function. J Cereb Blood Flow Metab 2006, 26:865-877.
52. Joe A.Y., Tielmann T., Bucerius J., Reinhardt M.J., Palmedo H., Maier W., Biersack H.J., Zobel A. Response-dependent differences in regional cerebral blood flow changes with citalopram in treatment of major depression. J Nucl Med 2006, 47:1319-1325.
53. Kalin N.H., Davidson R.J., Irwin W., Warner G., Orendi J.L., Sutton S.K., Mock B.J., Sorenson J.A., Lowe M., Turski P.A. Functional magnetic resonance imaging studies of emotional processing in normal and depressed patients: effects of venlafaxine. J Clin Psychiatry 1997, 58(16):32-39.
54. Kaymak S.U., Demir B., Oguz K.K., Senturk S., Ulug B. Antidepressant effect detected on proton magnetic resonance spectroscopy in drug-naive female patients with first-episode major depression. Psychiatry Clin Neurosci 2009, 63:350-356.
55. Keller M.B., Lavori P.W., Mueller T.I., Endicott J., Coryell W., Hirschfeld R.M., Shea T. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992, 49:809-816.
56. Kennedy S.H., Evans K.R., Kruger S., Mayberg H.S., Meyer J.H., McCann S., Arifuzzman A.I., Houle S., Vaccarino F.J. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001, 158:899-905.
57. Kennedy S.H., Konarski J.Z., Segal Z.V., Lau M.A., Bieling P.J., McIntyre R.S., Mayberg H.S. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 2007, 164:778-788.
58. Kent J.M., Coplan J.D., Gorman J.M. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998, 44:812-824.
59. Kohn Y., Freedman N., Lester H., Krausz Y., Chisin R., Lerer B., Bonne O. 99mTc-HMPAO SPECT study of cerebral perfusion after treatment with medication and electroconvulsive therapy in major depression. J Nucl Med 2007, 48:1273-1278.
60. Konarski J.Z., Kennedy S.H., Segal Z.V., Lau M.A., Bieling P.J., McIntyre R.S., Mayberg H.S. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci 2009, 34:175-180.
61. Kukolja J., Schlapfer T.E., Keysers C., Klingmuller D., Maier W., Fink G.R., Hurlemann R. Modeling a negative response bias in the human amygdala by noradrenergic-glucocorticoid interactions. J Neurosci 2008, 28:12868-12876.
62. Kumar J.S., Mann J.J. PET tracers for 5-HT(1A) receptors and uses thereof. Drug Discov Today 2007, 12:748-756.
63. Kumar P., Waiter G., Ahearn T., Milders M., Reid I., Steele J.D. Abnormal temporal difference reward-learning signals in major depression. Brain 2008, 131:2084-2093.
64. Lacerda A.L., Nicoletti M.A., Brambilla P., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Anatomical MRI study of basal ganglia in major depressive disorder. Psychiatry Res 2003, 124:129-140.
65. Lacerda A.L., Keshavan M.S., Hardan A.Y., Yorbik O., Brambilla P., Sassi R.B., Nicoletti M., Mallinger A.G., Frank E., Kupfer D.J., Soares J.C. Anatomic evaluation of the orbitofrontal cortex in major depressive disorder. Biol Psychiatry 2004, 55:353-358.
66. Lacerda A.L., Brambilla P., Sassi R.B., Nicoletti M.A., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Anatomical MRI study of corpus callosum in unipolar depression. J Psychiatr Res 2005, 39:347-354.
67. Little J.T., Ketter T.A., Kimbrell T.A., Dunn R.T., Benson B.E., Willis M.W., Luckenbaugh D.A., Post R.M. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry 2005, 57:220-228.
68. Lloyd G.G., Lishman W.A. Effect of depression on the speed of recall of pleasant and unpleasant experiences. Psychol Med 1975, 5:173-180.
69. Loubinoux I., Boulanouar K., Ranjeva J.P., Carel C., Berry I., Rascol O., Celsis P., Chollet F. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab 1999, 19:1365-1375.
70. Loubinoux I., Pariente J., Boulanouar K., Carel C., Manelfe C., Rascol O., Celsis P., Chollet F. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage 2002, 15:26-36.
71. Loubinoux I., Tombari D., Pariente J., Gerdelat-Mas A., Franceries X., Cassol E., Rascol O., Pastor J., Chollet F. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage 2005, 27:299-313.
72. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20:9104-9110.
73. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray A., Zarate C.A., Charney D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53:707-742.
74. Martin S.D., Martin E., Rai S.S., Richardson M.A., Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001, 58:641-648.
75. Martinot J.L., Hardy P., Feline A., Huret J.D., Mazoyer B., ttar-Levy D., Pappata S., Syrota A. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry 1990, 147:1313-1317.
76. Maurer D., Colt R. An evidence-based approach to the management of depression. Prim Care 2006, 33:923-941. vii.
77. Mayberg H.S. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997, 9:471-481.
78. Mayberg H.S. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003, 65:193-207.
79. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., Silva J.A., McGinnis S., Glass T.G., Martin C.C., Fox P.T. Cingulate function in depression: a potential predictor of treatment response. NeuroReport 1997, 8:1057-1061.
80. Mayberg H.S., Liotti M., Brannan S.K., McGinnis S., Mahurin R.K., Jerabek P.A., Silva J.A., Tekell J.L., Martin C.C., Lancaster J.L., Fox P.T. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999, 156:675-682.
81. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., Jerabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000, 48:830-843.
82. McCabe C., Mishor Z., Cowen P.J., Harmer C.J. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 2010, 67:439-445.
83. McKie S., Del-Ben C., Elliott R., Williams S., del V.N., Anderson I., Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 2005, 180:680-686.
84. McKinnon M.C., Yucel K., Nazarov A., MacQueen G.M. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009, 34:41-54.
85. Miskowiak K., Papadatou-Pastou M., Cowen P.J., Goodwin G.M., Norbury R., Harmer C.J. Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. Neuroimage 2007, 37:904-911.
86. Monkul E.S., Hatch J.P., Nicoletti M.A., Spence S., Brambilla P., Lacerda A.L., Sassi R.B., Mallinger A.G., Keshavan M.S., Soares J.C. Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder. Mol Psychiatry 2007, 12:360-366.
87. Murphy S.E., Norbury R., O'Sullivan U., Cowen P.J., Harmer C.J. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 2009, 194:535-540.
88. Norbury R., Mackay C.E., Cowen P.J., Goodwin G.M., Harmer C.J. The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol Psychiatry 2008, 13:1011-1020.
89. O'Doherty J., Rolls E.T., Francis S., Bowtell R., McGlone F., Kobal G., Renner B., Ahne G. Sensory-specific satiety-related olfactory activation of the human orbitofrontal cortex. NeuroReport 2000, 11:399-403.
90. Ogawa S., Menon R.S., Tank D.W., Kim S.G., Merkle H., Ellermann J.M., Ugurbil K. Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys J 1993, 64:803-812.
91. Onur O.A., Walter H., Schlaepfer T.E., Rehme A.K., Schmidt C., Keysers C., Maier W., Hurlemann R. Noradrenergic enhancement of amygdala responses to fear. Soc Cogn Affect Neurosci 2009, 4:119-126.
92. Patten S., Cipriani A., Brambilla P., Nose M., Barbui C. International dosage differences in fluoxetine clinical trials. Can J Psychiatry 2005, 50:31-38.
93. Peran P., Demonet J.F., Cardebat D. Paroxetine-induced modulation of cortical activity supporting language representations of action. Psychopharmacology (Berl) 2008, 195:487-496.
94. Perera T.D., Coplan J.D., Lisanby S.H., Lipira C.M., Arif M., Carpio C., Spitzer G., Santarelli L., Scharf B., Hen R., Rosoklija G., Sackeim H.A., Dwork A.J. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 2007, 27:4894-4901.
95. Petty F., Trivedi M.H., Fulton M., Rush A.J. Benzodiazepines as antidepressants: does GABA play a role in depression?. Biol Psychiatry 1995, 38:578-591.
96. Phan K.L., Wager T.D., Taylor S.F., Liberzon I. Functional neuroimaging studies of human emotions. CNS Spectr 2004, 9:258-266.
97. Phillips M.L., Drevets W.C., Rauch S.L., Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 2003, 54:515-528.
98. Posamentier M.T., Abdi H. Processing faces and facial expressions. Neuropsychol Rev 2003, 13:113-143.
99. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233.
100. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., Overholser J.C., Roth B.L., Stockmeier C.A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
101. Rapaport M.H. Future drugs for the treatment of depression: the need to look beyond monoamine systems. CNS Spectr 2009, 14:14-16.
102. Rauch S.L., Shin L.M., Phelps E.A. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research-past, present, and future. Biol Psychiatry 2006, 60:376-382.
103. Robertson B., Wang L., Diaz M.T., Aiello M., Gersing K., Beyer J., Mukundan S., McCarthy G., Doraiswamy P.M. Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. J Clin Psychiatry 2007, 68:261-267.
104. Rose E.J., Simonotto E., Spencer E.P., Ebmeier K.P. The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task. Psychopharmacology (Berl) 2006, 185:339-347.
105. Sala M., Perez J., Soloff P., Ucelli di N.S., Caverzasi E., Soares J.C., Brambilla P. Stress and hippocampal abnormalities in psychiatric disorders. Eur Neuropsychopharmacol 2004, 14:393-405.
106. Sala M., Coppa F., Cappucciati C., Brambilla P., d'Allio G., Caverzasi E., Barale F., De Ferrari G.M. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes. Curr Opin Investig Drugs 2006, 7:256-263.
107. Sala M., Lazzaretti M., De V.G., Caverzasi E., Barale F., d'Allio G., Brambilla P. Electrophysiological changes of cardiac function during antidepressant treatment. Ther Adv Cardiovasc Dis 2009, 3:29-43.
108. Sanacora G., Mason G.F., Rothman D.L., Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002, 159:663-665.
109. Schaefer H.S., Putnam K.M., Benca R.M., Davidson R.J. Event-related functional magnetic resonance imaging measures of neural activity to positive social stimuli in pre- and post-treatment depression. Biol Psychiatry 2006, 60:974-986.
110. Schmitt J.A., Wingen M., Ramaekers J.G., Evers E.A., Riedel W.J. Serotonin and human cognitive performance. Curr Pharm Des 2006, 12:2473-2486.
111. Sheline Y.I., Barch D.M., Donnelly J.M., Ollinger J.M., Snyder A.Z., Mintun M.A. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001, 50:651-658.
112. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003, 160:1516-1518.
113. Simmons A.N., Arce E., Lovero K.L., Stein M.B., Paulus M.P. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol 2009, 12:1009-1020.
114. Slade M., Amering M., Oades L. Recovery: an international perspective. Epidemiol Psichiatr Soc 2008, 17:128-137.
115. Takahashi H., Yahata N., Koeda M., Takano A., Asai K., Suhara T., Okubo Y. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage 2005, 27:991-1001.
116. Taylor M., Murphy S.E., Selvaraj S., Wylezinkska M., Jezzard P., Cowen P.J., Evans J. Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J Psychopharmacol 2008, 22:473-476.
117. Taylor M.J., Norbury R., Murphy S., Rudebeck S., Jezzard P., Cowen P.J. Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. J Psychopharmacol 2010, 24:1217-1221.
118. Verdoux H., Tournier M., Bigaud B. Pharmacoepidemiology of psychotropic drugs: examples of current research challenges on major public health issues. Epidemiol Psichiatr Soc 2009, 18:107-113.
119. Vollm B., Richardson P., McKie S., Elliott R., Deakin J.F., Anderson I.M. Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. Eur J Neurosci 2006, 23:552-560.
120. Vythilingam M., Vermetten E., Anderson G.M., Luckenbaugh D., Anderson E.R., Snow J., Staib L.H., Charney D.S., Bremner J.D. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 2004, 56:101-112.
121. Walsh N.D., Williams S.C., Brammer M.J., Bullmore E.T., Kim J., Suckling J., Mitterschiffthaler M.T., Cleare A.J., Pich E.M., Mehta M.A., Fu C.H. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry 2007, 62:1236-1243.
122. Williams J.W., Mulrow C.D., Chiquette E., Noel P.H., Aguilar C., Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000, 132:743-756.
123. Windischberger C., Lanzenberger R., Holik A., Spindelegger C., Stein P., Moser U., Gerstl F., Fink M., Moser E., Kasper S. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 2010, 49:1161-1170.
124. Wingen M., Kuypers K.P., van DV V., Formisano E., Ramaekers J.G. Sustained attention and serotonin: a pharmaco-fMRI study. Hum Psychopharmacol 2008, 23:221-230.
125. Yildiz-Yesiloglu A., Ankerst D.P. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 2006, 147:1-25.
126. Zachmann M., Tocci P., Nyhan W.L. The occurrence of gamma-aminobutyric acid in human tissues other than brain. J Biol Chem 1966, 241:1355-1358.